45 results about "Vimentin" patented technology

The invention belongs to the technical field of tumor micro-immune environments, and particularly relates to a kit for detecting a tumor micro-environment, a detection method and application, the kit comprises rare metal element labeled monoclonal antibodies, the rare metal element labeled monoclonal antibodies comprise 115In-CD20, 139La-Histone H3, 142Nd-CD56, 144Nd-CD14, 146Nd-Vimentin, 148Nd-Pan-CK, 151Eu-CD31, 156Gd-CD4, 158Gd-E-Cadrin, 159Tb-CD68, 162Dy-CD8a, 166Er-CD45, 167Er-CD15, 170Er-CD3, 171Yb-CD11c and 209Bi-alpha-SMA, and the rare metal element labeled monoclonal antibodies comprise The invention can be used for simultaneously detecting and researching the quantity, positioning and spatial topological relation of each cell component in a tumor microenvironment, and provides a multi-immunofluorescence detection kit and method for ubiquitous epithelial differentiation-derived tumors based on an imaging mass spectrum flow technique. A plurality of biomarkers can be analyzed at the same time by using multiple immunohistochemical staining and rare earth metal tag signal detection technologies, so that the aim of performing high-dimensional analysis on a tumor microenvironment is fulfilled according to cell composition, functional state and cell-cell space interaction relationship.

The invention provides an in-vitro anti-saccharification effect evaluation method and application thereof, and belongs to the technical field of skin saccharification resistance. A photoaging fibroblast model is adopted, after induction of an inducer, anti-saccharification evaluation is carried out by detecting the contents of collagen and waveform protein after application of a substance to be detected, and it is proved that the anti-saccharification effect of the anti-saccharification substance in the cell model is consistent with the result in human body effect evaluation; the evaluation method can be applied to screening and evaluation of anti-skin saccharification substances.

This invention belongs to the field of biomedicine and specifically relates to a method and kit for enriching circulating tumor cells (CTCs) in liver cancer using GPC3 in combination with MERTK. This method combines MERTK with traditional markers such as EpCAM, vimentin, and GPC3 to capture circulating tumor cells in liver cancer, achieving improved enrichment of CTCs. This method and its accompanying kit are widely applicable to early screening of liver cancer, postoperative recurrence monitoring, metastasis risk assessment, and personalized treatment management, and has promising prospects for clinical translation.

The invention relates to the technical field of biological medicines, in particular to application of an MAPK1IP1L gene or an MAPK1IP1L protein serving as an action target to preparation of a medicine for treating chronic kidney disease. According to the invention, the MAPK1IP1L gene overexpression (MAPK1IP1L OE) HK2 cell is constructed, and compared with a group in which the HK2 cell is not treated, the MAPK1IP1L OE has the advantage that the protein expression levels of FN, Collagen I, Vimentin and alpha-SMA are obviously reduced. Therefore, the chronic kidney disease can be improved and treated by overexpressing the MAPK1IP1L gene. Therefore, the invention relates to the application of the MAPK1IP1L gene or the MAPK1IP1L protein as the action target spot in preparation and / or screening of the medicine for treating the chronic kidney disease.

A method for the expression and / or for the amplification of the expression of thrombospondin-1, fibronectin, vimentin and / or mimecan in human skin. the method comprises applying to human skin at least one caviar extract which is capable of causing the expression and / or the amplification of the expression of thrombospondin-1, fibronectin, vimentin and / or mimecan in human skin.

The invention provides modRNA (Ribonucleic Acid) for treating obliterated bronchitis, and belongs to the technical field of bioengineering. The modRNA for treating obliterated bronchitis provided by the invention is composed of an IL-10 modRNA (Interleukin-10) and an IFN (Interferon)-alpha modRNA (Interferon-alpha) modRNA. The BO treatment effect is achieved by inhibiting bronchial epithelial cell epithelial-mesenchymal transition (EMT), the expression of alpha-SMA and Vimentin in lung tissue can be remarkably reduced, the expression of E-cadherin and Cytokeratin 5 can be up-regulated, microbronchial epithelial injury is repaired, collagen deposition is reduced, and the lung function is improved. The synergistic effect of the two is better than that of single gene therapy, the safety is high, and the controllability is strong.

VIM-specific nanobody and its applications belong to the field of biotechnology. To solve the problem of detecting vimentin (VIM), the key point is that the complementarity-determining regions (CDRs) of the nanobody include CDR1, CDR2, and CDR3 sequences: (I): (1) The amino acid sequence of CDR1 is shown in SEQ ID NO.27; (2) The amino acid sequence of CDR2 is shown in SEQ ID NO.33; and (3) The amino acid sequence of CDR3 is shown in SEQ ID NO.39. The effect is that the nanobody and its polypeptide of the present invention have high affinity and activity, can specifically recognize and bind to VIM, can be used for the capture and detection of VIM-positive cells, and can be applied to immunofluorescence analysis or immunohistochemical analysis through appropriate antibody labeling techniques.

The invention discloses application of METTL14 in inhibition of pituitary tumor cell proliferation and prognosis evaluation, and relates to the technical field of medicines. Experiments prove that when METTL14 is knocked out, E-cadherin can be lowered, and N-cadherin and waveform protein can be increased, so that the migration ability and proliferation and invasion ability of GH3 cells are promoted, and the tumor forming ability and in-vivo hormone level of pituitary growth hormone tumors are improved. Therefore, the METTL14 can be used for preparing a product for diagnosing or treating pituitary growth hormone adenoma, which is beneficial to theoretically researching pituitary adenoma and developing a novel targeted drug, and provides a new direction for finding a tumor marker or a new treatment strategy related to novel pituitary growth hormone adenoma diagnosis and controlling pituitary growth hormone adenoma.

A treatment composition for inhibiting systemic sclerosis Vimentin mutant protein activity by using an STAT6 inhibitor, which inhibits the expression of an M2 macrophage and a profibrotic T cell which are immunocytes related to systemic sclerosis, and increases the expression of a Treg, and inhibits the expression of TGF-β, Col1a1, and α-SMA which are fibrosis factors related to systemic sclerosis. The presence of a pSTAT6 expression CD8 T cell in a fibrosis tissue has been identified, and that the expression of a pSTAT6 expression CD8 T positive cell is controlled via injection of the STAT6 inhibitor. In an animal model with increased Vimentin-specific disease symptom activity, the STAT6 inhibitor inhibits antigen-specific tissue fibrosis of systemic sclerosis with activated disease symptoms, and that the STAT6 inhibitor inhibits the expression of IL-17 cytokine expression CD8 positive TRM capable of inducing fibrosis and cell inflammation which are systemic sclerosis diseases.

Disclosed herein are methods of detecting citrullinated polypeptides and / or citrullinated peptides. Citrullinated polypeptides, such as citrullinated vimentin, fibrinogen, and filaggrin, are expressed in various body fluids and / or tissues of individuals with autoimmune diseases, for example the synovium of subjects with rheumatoid arthritis. Further disclosed are methods of diagnosing, treating, selecting an individual for treatment of, and monitoring the treatment of autoimmune diseases, such as rheumatoid arthritis or hidradenitis suppurativa. Kits for use with the methods described herein are also provided.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a sperm-nourishing seed jade decoction and application thereof to improvement of endometrial receptivity, the sperm-nourishing seed jade decoction is composed of 30 g of radix rehmanniae preparata, 15 g of cornus officinalis, 15 g of radix paeoniae alba and 15 g of angelica sinensis, by inhibiting the epithelial-mesenchymal transition (EMT) process, the expression of E-cadherin and beta-catenin is up-regulated, the expression of Vimentin is down-regulated, and the endometrial receptivity is improved. Therefore, the stability and integrity of endometrial epithelium are maintained, intimal thickening, gland hyperplasia and angiogenesis are promoted, and an effective treatment strategy can be provided for infertility caused by thin endometrium.

Finding that vimentin is overexpressed in cancer cells and the PLK1-induced phosphorylation of vimentin leads to tumorigenesis and cancer metastasis, the present invention suggests two methods of reducing frequency of interaction between PLK1 and vimentin as a strategy for preventing tumorigenesis and cancer metastasis by reducing the migration and infiltration of cancer, and provides an application thereof.

The invention relates to the technical field of development of retinal ischemia reperfusion injury medicines, discloses application of Vimentin in preparation of medicines for preventing and treating retinal ischemia reperfusion injury, and discloses a safer and more effective medicine for treating retinal ischemia reperfusion injury. According to the invention, the nerve protection characteristic and good biocompatibility of Vimentin are utilized, so that the side effect of the medicine is reduced, and the treatment safety is improved. In addition, the Vimentin is proved to have a good effect in the aspects of reducing oxidative stress injury and improving mitochondrial functions, and a new therapeutic target is provided for treating the retinal ischemia reperfusion injury. Meanwhile, the Vimentin disclosed by the invention can be used as a supplement or replacement of an existing treatment method, provides a new treatment choice for patients, and is particularly suitable for patients with poor response to traditional treatment medicines.

The present invention discloses the use of MAPK pathway inhibitors in anti-pathogen infection. Specifically, the present invention discloses the use of a MAPK pathway inhibitor for preparing a pharmaceutical preparation or composition for anti-pathogen infection. The MAPK pathway inhibitor of the present invention controls the reproduction of pathogens in host cells and / or reduces the number of pathogens by promoting the diffusion of vimentin in cells, thereby effectively controlling pathogen infection.

A preparation method for and use of a scopoletin-functionalized magnetic nanoprobe. The preparation method comprises steps such as preparation of amino-terminal modified nanoparticles Fe3O4@SiO2-NH2, preparation of a photoaffinity linker-scopoletin conjugate, preparation of the scopoletin-functionalized magnetic nanoprobe, etc. The method features simple and rapid operation, and eliminates the need for prior clarification of the structure-activity relationship of the active compounds, without compromising all-round contact between the active compounds and target proteins. The prepared scopoletin-functionalized magnetic nanoprobe is used for target fishing in cellular and animal models of rheumatoid arthritis. After the captured target proteins are isolated and subjected to mass spectrometry identification, a western blot experiment successfully verifies vimentin as the target protein of scopoletin on HFLS-RA cell membranes, thereby providing a novel therapeutic target for rheumatoid arthritis.

The present application belongs to the technical field of tumor detection and cell separation, and particularly relates to a kit for separating and recovering after immunocapture of circulating tumor cells, a preparation method and application. The kit comprises an immunocapture module, a dissociation and recovery module, a cell protection module and elution and supplement factor solutions. The immunocapture module adopts magnetic microspheres modified by double antibody fusion proteins, can recognize multiple markers such as EpCAM and Vimentin, and realizes efficient capture of heterogeneous CTCs. The dissociation and recovery module uses a low-temperature buffer system and a cleavable cross-linking agent to release cells gently. The cell protection module maintains the integrity and activity of the cell membrane during the separation process. The method of the present application can ensure the capture efficiency while obtaining high-activity CTCs, and is suitable for single-cell sequencing, drug sensitivity analysis, organoid culture and patient-derived cell line construction and other preclinical research.

The present invention relates to a therapeutic composition for inhibiting the activity of a systemic sclerosis waveform protein variant using a STAT6 inhibitor, and has been confirmed that the STAT6 inhibitor inhibits the expression of fibrotic T cells and M2 macrophages, which are immune cells associated with systemic sclerosis, increases the expression of Treg, and inhibits the expression of fibrotic T cells and M2 macrophages, which are immune cells associated with systemic sclerosis. It has been confirmed that the expression of TGF-beta, Col1a1, and alpha-SMA, which are fibrosis factors associated with systemic sclerosis, is inhibited. Moreover, it has been confirmed that the expression of cell surface waveform protein, which is a waveform protein variant associated with systemic sclerosis, is reduced in skin tissue and lung tissue, and it has been confirmed that the waveform protein variant can be regulated. In addition, the presence of pSTAT6-expressed CD8T cells is confirmed in fibrotic tissues, and the expression of pSTAT6-expressed CD8T positive cells is confirmed to be regulated by administration of an STAT6 inhibitor. The STAT6 inhibitor also has been confirmed to inhibit the tissue fibrosis of systemic sclerosis in which the antigen-specific disease activity is increased in an animal model with increased waveform protein-specific disease activity, and to inhibit the expression of CD8-positive TRM expressed by an IL-17 cytokine capable of inducing inflammation and fibrosis, which is a systemic sclerosis cause cell.

The present invention belongs to the technical field of biochemical testing, and specifically provides a streptavidin-coupled antibody capture CTC detection kit and a preparation method thereof, wherein the kit includes components such as biotin-modified EpCAM monoclonal antibody and Vimentin monoclonal antibody, a pretreatment agent, a separation liquid, a fixative, a permeabilization agent, a blocking agent, a fluorescent staining liquid and a microfluidic chip. The bottom layer of the chip channel is solidified with streptavidin, and the upper layer is an asymmetric herring bone structure, which can enhance the binding efficiency between cells and antibodies. The kit achieves efficient capture of CTCs of different phenotypes through multi-antibody composite recognition, and combines immunofluorescence staining for multi-marker detection, with both sensitivity and specificity. The method has a standardized process flow and stable components, and is suitable for the enrichment and analysis of CTCs in clinical samples.

The invention discloses application of hAMSCs injected in different modes in preparation of drugs for improving pulmonary fibrosis EMT and apoptosis, and relates to the technical field of medicines. The hAMSCs provided by the invention are the third generation to the fifth generation of hAMSCs obtained by subculture, the hAMSCs highly express MSCs symbolic protein CD90, CD105, CD44 and CD73, and the hAMSCs lowly express CD11b, CD34, CD45 and CD19. The invention has proved that the expression of an epithelial marker E-cadherin can be increased by intratracheal or caudal vein injection of hAMSCs, and the expression of an interstitial marker vimentin is inhibited at the same time, so that the occurrence and development of IPF are prevented. A new thought is provided for preventing and preparing the IPF medicine.

This cell line is derived from a fish belonging to the family Anguillidae, expresses at least one selected from the group consisting of vimentin, CD29, CD73, and CD105, and has ability to accumulate fat. Also provided is a method for producing cells in which fat accumulates, the method involving a step for culturing the cell line derived from a fish belonging to the family Anguillidae in a culture medium, and causing fat to accumulate in the cells. Also provided is a fat production kit comprising the cell line derived from a fish belonging to the family Anguillidae, a fat accumulation culture medium, and a culture container.

The application discloses application of TACSTD2 protein in preparation of products for detecting and identifying human amniotic epithelial cells, and belongs to the technical field of biological medicines. The application proposes a protein marker for detecting and identifying human amniotic epithelial stem cells, which comprises TACSTD2 protein, or TACSTD2 protein combined with one or more selected from CD29, CD166, CD73, CD90, CD105, CD324, CD326, SSEA4, Nestin and Vimentin. The application further proposes application of a reagent for detecting TACSTD2 protein expression in preparation of products for detecting and identifying human amniotic epithelial cells, which is specifically highly expressed in human amniotic epithelial stem cells and can be used alone or in combination with other cells for detecting and identifying human amniotic epithelial cells.

The invention relates to the technical field of organoid culture, and provides a mouse tooth embryo organoid culture method which comprises the following steps: step 1, taking a first molar tooth embryo of the lower jaw of an SD (Sprague Dawley) rat of which the embryo is 18.5 days; 2, dissociating the tooth embryo tissue into single cells by adopting a mechanical shearing and compound enzyme digestion method, wherein the compound enzyme is prepared by mixing collagenase I, neutral protease II and deoxyribonuclease I according to a mass ratio of 2: 2: 1; step 3, embedding the single-cell suspension in matrigel at a concentration of 150000 cells / 50 [mu] L; and 4, adding a DMEM / F-12 culture medium containing growth factors, and culturing for 7 days under the conditions of 37 DEG C and 5% CO2. The cultured organoid forms a layered structure similar to a clock-shaped tooth embryo on the seventh day, contains epithelial cells (CK14 positive) and mesenchymal cells (Vimentin positive), can express an enameblast marker AMELX, an odontoblast marker DSPP and a tooth development key factor TGF-beta, and is highly consistent with the in-vivo tooth embryo development characteristic.

The invention belongs to the technical field of biochemical detection, and particularly provides a streptavidin coupled antibody capture CTC detection kit and a preparation method thereof.The kit comprises a biotin-modified EpCAM monoclonal antibody, a biotin-modified Vimentin monoclonal antibody, a pretreatment agent, a separation solution, a stationary solution, a permeation agent, a sealing agent, a fluorescent staining solution, a micro-fluidic chip and other components. Streptavidin is solidified at the bottom layer of the chip channel, and the upper layer is of an asymmetric herring bone structure, so that the binding efficiency of cells and antibodies can be enhanced. The kit realizes efficient capture of different phenotypes of CTCs through multi-antibody composite recognition, performs multi-marker detection in combination with immunofluorescent staining, and has both sensitivity and specificity. The method is standard in technological process, stable in component and suitable for enrichment and analysis of CTC in a clinical sample.

This invention relates to the field of pharmaceutical technology, disclosing the application of a synthetic peptide that targets and inhibits GRP in the preparation of a drug for treating diabetic neuropathy. The synthetic peptide sequence is SWYLILRIENGKLVKEVVHVPD. This sequence targets and blocks the GRP / vimentin signaling axis. Vimentin is specifically expressed by astrocytes and is a characteristic protein of astrocyte activation. Astrocyte activation can cause central sensitization, leading to chronic pain and other chronic diseases. This synthetic peptide sequence is used in the preparation of a drug for treating diabetic neuropathy. This invention provides a GRP-targeting inhibitory peptide that has a good therapeutic effect on chronic pain, laying the foundation for clinical treatment of chronic pain and possessing significant application and promotion value.

The invention relates to the technical field of biological medicine, in particular to application of AK4 protein or AK4 gene as a target spot in screening of drugs for treating chronic kidney diseases. By constructing a renal fibrosis model, it is found that the expression level of AK4 protein in the renal fibrosis model is remarkably reduced, and the expression levels of FN, Collagen I, Vimentin and alpha-SMA protein are remarkably increased. The AK4 gene is overexpressed or knocked out in renal tubular epithelial cells, and the fact that the protein expression levels of FN, Vimentin and alpha-SMA can be remarkably increased by the cells with the AK4 gene knocked out is found, and the opposite situation is shown by the cells with the overexpressed AK4 gene. Therefore, the AK4 protein or the AK4 gene can be used as an action target spot for screening the medicine for treating the renal fibrosis; meanwhile, the AK4 protein or an activator of the AK4 gene can be used as a medicine for treating chronic kidney diseases. The invention provides a new way for the treatment of chronic kidney disease.

The invention belongs to the technical field of fluorescence detection, and particularly relates to a multi-target circulating tumor cell quality control kit as well as a preparation method and application thereof. The kit comprises multi-marker substance control microspheres, a fixed preservation system and a subpackaging unit, the microspheres are 2-6 [mu] m polymer substrate particles, the surfaces of the microspheres are covalently coupled with recombinant antigen proteins such as EpCAM, CK8, Vimentin and CD45, and different microsphere subgroups present multiple antigen combinations and are used for simulating marker characteristics of circulating tumor cells and immune cells. Through cross-linking fixation and freeze-drying protection treatment, the obtained quality control microspheres have good antigen stability and channel recognition performance, and are suitable for multi-platform quality control of a flow cytometer, a multi-channel immunofluorescence system and the like. The kit can replace traditional quality control cells, and standard, low-risk and long-term storage multi-target detection quality control is realized.

The invention belongs to the technical field of tumor detection and cell separation, and particularly relates to a kit for separating and recycling circulating tumor cells after immunocapture, a preparation method and application. The kit comprises an immunocapture module, a dissociation recovery module, a cell protection module and an elution and supplement factor solution, the immunocapture module adopts magnetic microspheres modified by double-antibody fusion protein and can simultaneously recognize various markers such as EpCAM and Vimentin, and efficient capture of heterogeneity CTCs is achieved; the dissociation and recovery module gently releases cells by using a low-temperature buffer system and a cleavable cross-linking agent; the cell protection module maintains the integrity and activity of cell membranes in the separation process. According to the method, the high-activity CTCs can be obtained while the capture efficiency is guaranteed, and the method is suitable for scientific research and preclinical research such as single cell sequencing, drug sensitivity analysis, organoid culture and patient-derived cell line construction.

The invention discloses a method for interaction of parasitic protein and protein in host cells, and belongs to the technical field of genetic engineering. The invention provides an isospora hyocystis ENO2 protein and pig intestine epithelial cell waveform protein interaction method, interaction conditions are optimized, the influence of the dosages of the two proteins on the interaction conditions is explored, conditions suitable for interaction of parasites and host cells are found more accurately, the success rate of experiments is increased, and the experiment cost is reduced. Therefore, a theoretical basis is provided for researching isospora hyocystis ENO2 and unknown proteins of the epithelial cells of the pig intestines, and the problem that interaction conditions of parasitic proteins and proteins in host cells are difficult to succeed at present is solved.

The invention provides a proliferation culture medium for long-term stable passage of bovine-derived cells, a method for promoting long-term stable passage of bovine-derived cells and application of the proliferation culture medium. The proliferation culture medium comprises the following components: a complete culture medium, cycloastragenol and metformin hydrochloride. Researches show that the proliferation culture medium can make bovine embryo fibroblasts (BFFs) break through the proliferation limit in the in-vitro subculture process, a continuous cell line is formed, and production of cell culture meat products with excellent quality is facilitated. The culture medium provided by the invention can support continuous passage of BFFs to 145 generations, and the cell type of the bovine embryo fibroblast cell line subjected to passage to 145 generations is unchanged, so that the culture medium has the advantage of long-term stable passage. Through induction of the proliferation culture medium, the BFFs can break through aging limitation, long-term stable passage (more than or equal to 100 generations) is realized, the waveform protein positive rate of more than 90% is maintained, the requirement of mass production of cell culture meat on the cell number is met, and the proliferation culture medium has a very wide application prospect.

The disclosure provides methods for identifying genomic loci (e.g., vimentin and / or SqBE18) that are differentially methylated in metaplasias (e.g., Barrett's esophagus) and / or neoplastic cancers (e.g., esophageal cancers). Identification of methylated genomic loci has numerous uses, including for example, to characterize disease risk, to predict responsiveness to therapy, to non-invasively diagnose subjects and to treat subjects determined to have gastrointestinal metaplasias and / or neoplasias.